Objective Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that preferentially catalyzes the S-methylation of aromatic and heterocyclic sulfhydryl compounds, including Azathioprine (AZA). It has been reported that the level of AZA toxicity is dependent on the
TPMT genotypes in Caucasian individuals; we thus investigated this relationship in Japanese.
Methods The
TPMT genotype was determined using peripheral blood cell DNA obtained from 36 Japanese patients with rheumatic diseases who were treated with AZA, by polymerase chain reaction (PCR) technique. Duration of AZA administration, white blood cell counts before and after AZA administration, and side effects were investigated in each subject, and were compared between the patients with or without
TPMT mutation.
Results The
TPMT allelotype was
TPMT*1/TPMT*1 in 33 (91.7%) and
TPMT*1/TPMT*3C in 3 (8.3%) individuals. All 3 patients (100%) with the mutant
TPMT allele (
TPMT*3C) discontinued AZA treatment due to leucopenia while only 4 patients (12%) without mutant
TPMT alleles showed leucopenia (p=0.0049, Fisher's exact test). However, leucopenia developed relatively late in patients with mutant
TPMT.
Conclusion The
TPMT mutant allele,
TPMT*3C, also exists in Japanese individuals, and the bone marrow toxicity of AZA is likely stronger in patients with this mutant allele.
(Internal Medicine 38: 944-947, 1999)
抄録全体を表示